Gene
POLE
POLE is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (28), Actionable biomarkers (3), Trial mentions (73), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention POLE. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 15 of 8,738 | 0.17% | not measured | |
| 2025 | 10 of 8,875 | 0.11% | not measured | |
| 2024 | 6 of 8,597 | 0.07% | not measured | |
| 2023 | 9 of 8,275 | 0.11% | 0 of 11,460 | 0.00% |
| 2022 | 5 of 8,285 | 0.06% | 1 of 13,598 | 0.01% |
| 2021 | 6 of 8,692 | 0.07% | 0 of 15,045 | 0.00% |
| 2020 | 4 of 7,640 | 0.05% | 2 of 14,459 | 0.01% |
| 2019 | 2 of 7,300 | 0.03% | 0 of 12,159 | 0.00% |
| 2018 | 6 of 6,927 | 0.09% | 1 of 11,854 | 0.01% |
| 2017 | 6 of 6,558 | 0.09% | 1 of 11,595 | 0.01% |
Showing 10 of 37 years.
Assay-provider ledger (28)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Diatech Pharmacogenetics | Diagnostic provider | Clinical validation | 1 | July 01, 2026 |
| Leica BioSystems | Unclassified | Clinical validation | 1 | July 01, 2026 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 3 | July 01, 2026 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validationAnalytical validation | 2 | July 01, 2026 |
| Foundation Medicine | Diagnostic provider | Clinical validation | 1 | October 01, 2025 |
Showing 5 of 28 assay-provider companies.
Actionable biomarkers (3)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| POLE oncogenic mutation | Pd1 Ab Inhibitors | response-associated | colorectal adenocarcinoma | Cancer Genome Interpreter |
| POLE (268-471) | Pd1 Ab Inhibitors | response-associated | endometrial carcinoma | Cancer Genome Interpreter |
| POLE (268-471) | Pd1 Ab Inhibitors | response-associated | glioma | Cancer Genome Interpreter |
Trial mentions (73)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT07775859 | Trial biospecimen (AACT) |
| NCT07642323 | Trial eligibility (AACT) |
| NCT06772415 | Trial eligibility (AACT) |
| NCT07209449 | Trial eligibility (AACT) |
| NCT04500548 | Trial eligibility (AACT) |
Showing 5 of 73 trial mentions.
Target-disease associations (518)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AIDS dementia | infectious disease | Literature (Europe PMC) |
| APC-related attenuated familial adenomatous polyposis | cancer or benign tumor | Mouse knockout (IMPC) |
| AXIN2-related attenuated familial adenomatous polyposis | cancer or benign tumor | Mouse knockout (IMPC) |
| Alpha-1-antitrypsin deficiency | gastrointestinal disease | Mouse knockout (IMPC) |
| Alpha-thalassemia - myelodysplastic syndrome | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 518 associations.
Vendor sourcing (308)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The variant is not observed in the gnomAD v2.1.1 dataset. Canonical splice site: predicted to alter splicing and result in a loss or disruption of normal pro... | View ClinVar record SCV002521185.1 |
| ARUP Laboratories (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The POLE c.4057A>G; p.Ser1353Gly variant (rs141619382) is reported in the literature in individuals affected with cancer, but without clear disease associati... | View ClinVar record SCV003800455.3 |
| AbbVie Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients must have a histologically documented (either primary or metastatic site) diagnosis of advanced solid tumor cancer (stage IV or unresectable) o... | View trial NCT03061188 |
| AbbVie Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | POLE | View trial NCT03061188 |
| Agenus Inc | Trial collaborator | Named in trial exclusion criteriaTrial eligibility criteria | : * Presence of metastatic or recurrent disease. * Known DNA polymerase epsilon (POLE) or DNA polymerase delta (POLD) activating mutation. * R1 (microscopic... | View trial NCT07227636 |
Showing 5 of 308 sourcing records.
Trial-cited literature (11)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. | Nature genetics | 2022 | 63 |
| Human Inborn Errors of Immunity: 2019 Update on the Classification from the International Union of Immunological Societies Expert Committee. | Journal of clinical immunology | 2020 | 805 |
| Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. | Cancers | 2020 | 31 |
| International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. | Journal of clinical immunology | 2018 | 580 |
| Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. | Cancer | 2017 | 788 |
Showing 5 of 11 papers.
Protein variant mentions (260)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A1022V | 1 | 2015 | PMID 25741868 |
| p.A1126V | 1 | 2016 | PMID 26467025 |
| p.A1224S | 1 | 2015 | PMID 25741868 |
| p.A1224V | 1 | 2015 | PMID 25741868 |
| p.A1323V | 2 | 2015 to 2016 | PMID 26467025, PMID 25741868 |
Showing 5 of 260 variants.
Human sample screening reference (2)
Shown in this order: alphabetical by variant.
| Variant | GDC project | Disease / site | Affected cases | Profiled cases | Observed frequency | 95% interval |
|---|---|---|---|---|---|---|
| p.L424V | TCGA-BRCA | Cystic, Mucinous and Serous Neoplasms; Adenomas and Adenocarcinomas; Fibroepithelial Neoplasms; Basal Cell Neoplasms; Ductal and Lobular Neoplasms; Epithelial Neoplasms, NOS; Squamous Cell Neoplasms; Complex Epithelial Neoplasms; Adnexal and Skin Appendage Neoplasms; Breast | 1 | 1,098 | 0.09% | 0.02% to 0.51% |
| p.L424V | TCGA-UCEC | Not Reported; Epithelial Neoplasms, NOS; Adenomas and Adenocarcinomas; Cystic, Mucinous and Serous Neoplasms; Corpus uteri; Uterus, NOS | 1 | 559 | 0.18% | 0.03% to 1.01% |
Literature-extracted relations (2)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Colorectal Neoplasms | Disease | associate |
A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine. | 2015 |
| Ovarian Neoplasms | Disease | associate |
A novel POLE mutation associated with cancers of colon, pancreas, ovaries and small intestine. | 2015 |
Organizations publishing (24)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Mount Sinai Health System | Hospital | 5 | 2014 to 2022 |
| Boston Children's Hospital | Hospital | 4 | 2014 to 2020 |
| Government of the United States of America | Government | 4 | 2014 to 2020 |
| Kuwait University | Academic | 4 | 2014 to 2020 |
| St Vincent's Hospital Sydney | Hospital | 2 | 2018 to 2020 |
Showing 5 of 24 organizations.
Where POLE appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- immune system disease
- infectious disease
- measurement
- nervous system disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
412 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and fda biomarker qualification projects.